n.a. (SHP)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)

Latest News

ADYNOVATE Phase 3 Efficacy And Safety Data In Children To Be Showcased During International Congress Of The World Federation Of Hemophilia

ADYNOVATE Phase 3 Efficacy And Safety Data In Children To Be Showcased During International Congress Of The World Federation Of Hemophilia

Shire committed to advancing treatment and raising standards of care for hemophilia patients around the world

Shire Reinforces Commitment In Hematology With Robust Data Presented At International Congress Of The World Federation Of Hemophilia

Shire Reinforces Commitment In Hematology With Robust Data Presented At International Congress Of The World Federation Of Hemophilia

More than 40 presentations and sessions feature broad pipeline and proven factor replacement portfolio, with new innovation on outcomes, safety and efficacy measures

Shire And Kamada Announce FDA Approval Of Expanded Label For Self-infusion Of GLASSIA For The Treatment Of Emphysema Due To Severe AAT Deficiency

Shire And Kamada Announce FDA Approval Of Expanded Label For Self-infusion Of GLASSIA For The Treatment Of Emphysema Due To Severe AAT Deficiency

GLASSIA [Alpha-1 Proteinase Inhibitor (Human)] is the only FDA approved alpha-1 antitrypsin (AAT) augmentation treatment that patients can self-infuse at home

Baxalta Shareholders Vote To Approve Combination

Baxalta Shareholders Vote To Approve Combination

Baxalta Incorporated (NYSE:BXLT) today announced the results of a vote on the proposals identified in the definitive proxy statement/prospectus, dated April 18, 2016, at a special meeting of shareholders held earlier this...

Shire To Present New Research At 2016 American Psychiatric Association Annual Meeting

Shire To Present New Research At 2016 American Psychiatric Association Annual Meeting

Reinforces Long-Standing Commitment to Furthering Knowledge of B.E.D. and ADHD

Shire Submits NDA To FDA For New Formulation Of Vyvanse® (lisdexamfetamine Dimesylate) CII As Chewable Tablets

Shire Submits NDA To FDA For New Formulation Of Vyvanse® (lisdexamfetamine Dimesylate) CII As Chewable Tablets

New formulation, in adherence with approved indications, intended for children, adolescents and adults with difficulty swallowing or opening capsules